Business Context and Reporting Period
This Form 6-K filing by InflaRx N.V. reports the results of the Annual General Meeting of Shareholders held on April 26, 2023. The filing date is April 27, 2023. The meeting addressed governance matters, including the approval of statutory accounts for the fiscal year ended December 31, 2022, and the appointment of new directors.
Financial Metrics
The filing text does not provide specific financial values for revenue, profit, cash flow, margins, debt, or liquidity. It confirms only that shareholders approved the adoption of the Dutch statutory annual accounts for the fiscal year ended December 31, 2022, without detailing the figures contained therein.
Material Changes
There are no material financial changes reported in this document. The primary changes relate to corporate governance and shareholder authorizations:
- Approval of the 2022 statutory annual accounts.
- Instruction to Ernst & Young Accountants LLP for the 2023 external audit.
- Release from liability for directors regarding the 2022 fiscal year.
- Appointment of Ms. Hege Hellstrom as a non-executive director.
- Extension of Board authorization to issue shares, grant subscription rights, limit pre-emption rights, and acquire company shares.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The document is strictly a record of shareholder voting outcomes.
Key Facts for Investor Verification
- Verify the specific financial figures in the approved 2022 Dutch statutory annual accounts, as they are not listed in this filing.
- Confirm the impact of the new Board authorizations on potential future share dilution or capital structure changes.
- Review the background and qualifications of the newly appointed non-executive director, Ms. Hege Hellstrom.
- Check subsequent filings for the detailed 2022 financial statements referenced in Agenda Item 3.